Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a
single arm, open label study evaluating VSLI plus rituximab in adults with aggressive
relapsed or refractory non-Hodgkin's lymphoma.